Atlas Trials

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Clinical trial NCT05071300 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05071300
Sponsor
Ionis Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Start date
2022-01-04
Primary completion
2029-08-01
Enrollment
151

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.